The End Of Generics Mergers? Too Much Effort, No Reward!

There has been $150bn worth of merger and acquisition activity since 2012 in the generic medicines arena, yet the sector is more fragmented than it was five years ago. CEOs and analysts from the generics sector believe that investor-propelled moves towards greater consolidation have been thwarted by the market agility of smaller companies. And now the cost of M&A has burdened major generics firms with debt.

Salmon run
Swimming against the current: is it worth trying to become a big fish in generics? • Source: Shutterstock

Each year since 2012 has seen record levels of mergers and acquisitions, with the peak of activity in 2015 (when deal values totalled $77bn) including the acquisition by Teva Pharmaceutical Industries Ltd. of Actavis generics (Allergan PLC), Pfizer Inc. buying Hospira Inc. and Endo International PLC acquiring Par Pharmaceutical. Either side of that peak, Mylan NV acquired Abbott Laboratories Inc.'s US generics business and Meda AB. Despite this, according to figures from McKinsey & Company, the aggregate market share of the top five generic medicines companies in markets such as France, Germany, and the US has fallen between 2012 and 2016 (Table 1).

Speaking at the CEO and Analyst Panel of the annual Medicines for Europe/IGBA meeting in Lisbon on 16 June, McKinsey...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

 

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

 
• By 

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Sanofi’s Blueprint buy; AstraZeneca’s breast cancer resistance results at ASCO; BMS and BioNTech’s big bispecific deal; Kymera’s Dupixent in a pill; and Degron’s CEO on pipeline and strategy.

Chinese Biotech VC/PE Fundings Rise But Still Modest

 

LTZ Therapeutics and Beijing Sungen Biomedical are among the Chinese biotechs raising new funding, of around $40m each, based on their clinical assets with novel mechanisms of action. While fundings have risen, they remain moderate however.

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By 

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.